Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function

Pimecrolimus and Epidermal Barrier Function

NCT01132079 ·Status: COMPLETED ·Phase: NA

Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis

NCT00535691 ·Status: COMPLETED ·Phase: PHASE2

Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis

NCT03361215 ·Status: RECRUITING

Tralokinumab for Dupilumab Failures

NCT06773455 ·Status: TERMINATED ·Phase: PHASE4

Skin Barrier Abnormalities and Oxidative Stress Response

NCT04606615 ·Status: UNKNOWN

Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

NCT05388760 ·Status: COMPLETED ·Phase: PHASE2

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

NCT02496546 ·Status: COMPLETED ·Phase: PHASE1

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

NCT05958407 ·Status: COMPLETED ·Phase: PHASE3

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7

NCT03761537 ·Status: COMPLETED ·Phase: PHASE3

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

NCT03587805 ·Status: COMPLETED ·Phase: PHASE3

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

NCT03526861 ·Status: COMPLETED ·Phase: PHASE3

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

NCT04753034 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis

NCT04761978 ·Status: WITHDRAWN

A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients

NCT01552629 ·Status: COMPLETED ·Phase: PHASE2

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT05990725 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651 ·Status: COMPLETED ·Phase: PHASE3

Elidel-Study: Elidel in Patients With Atopic Dermatitis

NCT00180141 ·Status: COMPLETED ·Phase: PHASE4

A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.

NCT04836858 ·Status: COMPLETED ·Phase: PHASE2

Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood

NCT04398758 ·Status: UNKNOWN ·Phase: PHASE3

Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit

NCT00654355 ·Status: COMPLETED ·Phase: PHASE4

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377 ·Status: COMPLETED ·Phase: PHASE2

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

NCT05938478 ·Status: RECRUITING

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

NCT03796676 ·Status: COMPLETED ·Phase: PHASE3

Atopic Dermatitis (AD) and Food Allergy

NCT03168113 ·Status: COMPLETED

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis

NCT04587453 ·Status: COMPLETED ·Phase: PHASE3